No Data
No Data
Institutional Investors May Adopt Severe Steps After Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) Latest 12% Drop Adds to a Year Losses
Key Insights Significantly high institutional ownership implies Allogene Therapeutics' stock price is sensitive to their trading actions A total of 8 investors have a majority stake in the company w
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T)
JMP Securities Maintains Allogene Therapeutics(ALLO.US) With Hold Rating
JMP Securities analyst Reni Benjamin maintains $Allogene Therapeutics(ALLO.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 35.5% and a total average return of -6.
Why James Hardie Industries Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of James Hardie Industries plc (NYSE:JHX) fell sharply during Tuesday's session after the company reported worse-than-expected quarterly financial results.James Hardie Industries posted adjuste
Allogene Therapeutics Shares Jump 10% on Share Purchases by Chairman, CEO
By Denny Jacob Allogene Therapeutics shares jumped 10% on Tuesday after company insiders bought up shares, often an indication of confidence by leadership. Shares were trading around $2.83. The stoc
Insider Trading: Allogene Therapeutics' Insider Buys Shares Worth $5M
No Data